Engineered SNIPRs transform CAR T-cell precision for safer cancer therapy

Researchers developed SNIPRs, innovative receptors that sense soluble ligands, enabling precise therapeutic control in CAR T-cells. This breakthrough enhances tumor targeting while reducing off-target effects, paving the way for advanced synthetic biology applications.

Novo Nordisk to spend $1.2B for new rare disease drug factory in Denmark

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

December 17, 2024

Hospital diversity linked to higher mortality rates for ventilated patients

The odds of death for patients receiving mechanical ventilation for pneumonia or sepsis increase along with the diversity of hospitals’ patient populations, suggesting more systemic

May 20, 2024

Lovo-Cel ‘Life-Changing, Transformative’ in Sickle Cell Disease

SAN DIEGO — A one-time treatment with lovotibeglogene autotemcel (Lyfgenia, lovo-cel) achieved near complete resolution of severe pain crises in patients with sickle cell disease

December 11, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.